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Abstract
Background: Retinitis pigmentosa (RP) is a group of hereditary retinal neurodegenerative conditions characterized
by primary dysfunction and death of photoreceptor cells, resulting in visual loss and, eventually, blindness. To date,
no effective therapies have been transferred to clinic. Given the diverse genetic etiology of RP, targeting common
cellular and molecular retinal alterations has emerged as a potential therapeutic strategy.
Methods: Using the Pde6brd10/rd10 mouse model of RP, we investigated the effects of daily intraperitoneal
administration of VP3.15, a small-molecule heterocyclic GSK-3 inhibitor. Gene expression was analyzed by
quantitative PCR and protein expression and phosphorylation by Western blot. Photoreceptor preservation was
evaluated by histological analysis and visual function was assessed by electroretinography.
Results: In rd10 retinas, increased expression of pro-inflammatory markers and reactive gliosis coincided with the
early stages of retinal degeneration. Compared with wild-type controls, GSK-3β expression (mRNA and protein)
remained unchanged during the retinal degeneration period. However, levels of GSK-3βSer9 and its regulator
AktSer473 were increased in rd10 versus wild-type retinas. In vivo administration of VP3.15 reduced photoreceptor
cell loss and preserved visual function. This neuroprotective effect was accompanied by a decrease in the
expression of neuroinflammatory markers.
Conclusions: These results provide proof of concept of the therapeutic potential of VP3.15 for the treatment of
retinal neurodegenerative conditions in general, and RP in particular.
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Background
Inherited retinal dystrophies, which include retinitis pig-
mentosa (RP), are a group of genetic diseases caused by
mutations in over 300 genes and loci (http://www.sph.
uth.tmc.edu/Retnet/disease.htm). RP is a retinal neuro-
degenerative condition characterized by primary dys-
function and death of photoreceptor cells, resulting in
vision loss and, ultimately, blindness [1]. Although
several experimental therapies have advanced to clinical
trials (https://clinicaltrials.gov/ct2/results?term=retinitis
+pigmentosa&Search=Search), neither approved treat-
ments nor preventive therapies for RP are currently
available. Its status as a rare disease and its diverse gen-
etic etiology emphasize the importance of identifying
shared pathological mechanisms independent of the
causative mutation. Targeting common cellular and mo-
lecular retinal responses to mutations could benefit a
significant number of RP patients, as well as those with
other retinal dystrophies without an exclusively genetic
etiology (e.g., glaucoma, age-related macular degener-
ation, diabetic retinopathy). Recent studies suggest that
retinal neurodegeneration is associated with a broad in-
flammatory response in the retina. This response
appears to be mutation-independent and involves
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microglial activation, reactive macrogliosis, and the pro-
duction of pro-inflammatory cytokines [2–5].
GSK-3 is a serine/threonine kinase that exists as 2
highly homologous isoforms, GSK-3α and GSK-3β, each
encoded by a distinct gene. GSK-3β is predominantly
expressed in the central nervous system (CNS) [6]. Al-
though initially identified as a glycogen synthesis enzyme
(the role for which it was named), GSK-3 is currently
considered a multitask enzyme involved in the regula-
tion of diverse cellular functions owing to its broad
substrate spectrum [7, 8]. In particular, GSK-3 plays a
pivotal role in regulating the balance between pro-
inflammatory and anti-inflammatory cellular responses.
Consequently, GSK-3 is considered a potential thera-
peutic target for diseases with an inflammatory compo-
nent. The therapeutic potential of GSK-3 modulators is
currently being studied in a variety of neuroinflamma-
tory diseases. These include psychiatric and neurodegen-
erative disorders, as well as retinal dystrophies; as part
of the CNS, the retina shares many physiological and
pathological traits with the brain [9].
Employing a chemical genetic approach, we recently in-
vestigated the neuroprotective effects of 3 chemically di-
verse GSK-3 modulators in photoreceptor cells [10]. In
the present study we selected one of these compounds,
VP3.15, based on its favorable pharmacokinetic and IC50
properties. This molecule is a 5-imino-thiadiazole that has
been described not only as substrate-competitive GSK-3
inhibitor [11], but also as allosteric inhibitor of PDE7 [12].
We sought to validate in vivo the potential of GSK-3
as a therapeutic target for the treatment of RP, and to
demonstrate the therapeutic potential of VP3.15 in this
neurodegenerative condition. We characterized the
expression of GSK-3β and its inactive serine-9-
phosphorylated form in the dystrophic retina of the rd10
mouse, a model of RP. Moreover, we demonstrated that
chronic systemic in vivo VP3.15 treatment preserved vis-
ual function by delaying neurodegeneration. Our results
indicate that VP3.15 is an innovative drug candidate for
the treatment of RP.
Methods
Animals and drug delivery
The rd10 mouse model of retinal neurodegeneration
carries a homozygous phosphodiesterase 6b mutation
(Pde6brd10/rd10) on a C57BL/6 J background. Mice were
kindly provided by Bo Chang from The Jackson
Laboratory (Bar Harbor, ME, USA). Wild type (WT)
control mice of the same background were also obtained
from The Jackson Laboratory. All animals were housed
and handled in accordance with the ARVO statement
for the Use of Animals in Ophthalmic and Vision
Research, European Union guidelines, and those of the
local ethics committees of the CSIC and the Comunidad
de Madrid. Mice were bred at the CIB core facilities on
a 12/12-h light/dark cycle.
VP3.15 was synthesized in our laboratory as previously
described [11]. This small molecule is a member of the
iminothiadiazole family, the first group of substrate-
competitive GSK-3 inhibitors described ([11]; see
Additional file 1: Figure S1 for the structure data).
The dose administrated was selected based on phar-
macokinetic and IC50 data ([11–13] and data not
shown). Mice received daily intraperitoneal injections
of vehicle (10% DMSO, 0.9% NaCl) or VP3.15
(10 mg/kg) for the indicated period of time.
IP administration was selected based on the ability of
VP3.15 to cross the brain blood barrier [13] and the ne-
cessity of performing repetitive administration without
damaging the eye.
Electroretinography
Mice underwent electroretinographic recordings (ERG)
at different time points, using a previously described
ERG protocol [14]. ERGs were performed by an observer
blind to treatment. ERG signals were amplified and band
filtered between 0.3 Hz and 1000 Hz (CP511 Preampli-
fier, Grass Instruments, Quincy, MA, USA) and digitized
at 10 kHz using a PowerLab acquisition data card (AD
Instruments Ltd., Oxfordshire, UK). Graphical represen-
tations of the signals recorded and the control light
stimuli were generated using Scope v6.4 PowerLab soft-
ware. ERG wave amplitudes were measured off-line and
the results averaged.
Histology and immunostaining
Mice were euthanized at the indicated ages and their
eyes enucleated. The right eye was processed for histo-
logical analyses and the left eye for retinal RNA extrac-
tion. For histological analyses, eyes were fixed for 1 h in
4% (w/v) paraformaldehyde in 0.1 M phosphate buffer
(PB), pH 7.4, and then cryoprotected by incubation in
increasing concentrations of sucrose (final concentration
50% (w/v) in PB). The eyes were then embedded in
Tissue-Tek OCT (Sakura Finetec, Torrance, CA, USA)
and frozen on isopropanol/dry ice. Cryostat equatorial
sections (12 μm) were mounted on Superfrost® Plus
slides (Thermo Scientific, Massachusetts, USA), dried at
room temperature, and stored at − 20 °C. Before per-
forming further analyses, sections were fixed in acetone
for 10 min at − 20 °C and dried at 65 °C for 10 min.
After rinsing in PBS and permeation with 1% (w/v) Tri-
ton X-100 in PBS, sections were blocked in BGT (2.5 g/
L BSA, 100 mM glycine, 0.25% (w/v) Triton X-100 in
PBS) for 1 h and then incubated overnight at 4 °C with
primary antibodies (Table 1) diluted in BGT. Sections in-
cubated in the absence of primary antibody were used as
specificity controls. After rinsing in PBS and incubation
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with the appropriate secondary antibodies (Table 1), sec-
tions were stained with DAPI (4′,6-diamidino-2-pheny-
lindole; Sigma-Aldrich Corp., St. Louis, MO, USA) and
coverslipped with Fluoromont-G.
To assess preservation of the photoreceptor layer, we
compared the thickness of the ONL (which primarily
contains photoreceptors) with that of the corresponding
INL (which contains bipolar, horizontal, and amacrine
neurons and Müller glial cell bodies), and quantified the
length of rod and cone outer segments (OS). Three sec-
tions per eye were analyzed: for each section, one image
was captured for each of the 6 retinal zones (T1, T2, T3,
T4, T5, and T6; Additional file 2: Figure S2). In each
image, 3 measurements were recorded at random posi-
tions to obtain an average value per retinal zone per sec-
tion. Measurements were performed using the “freehand
line” and “measure” tools in Fiji software. The ONL
thickness was normalized to that of the INL (not af-
fected by the degeneration at this stage) to correct for
possible inclinations of the sectioning plane.
Immunoblots
Protein extraction was carried out by sonicating individ-
ual retinas in RIPA lysis buffer (containing 2 mM
Na3VO4, 10 mM NaF, and 4 mM Na4P2O7) and chilling
the resulting solution on ice for 30 min. Protein (30 μg)
from each sample was fractionated by electrophoresis on
precast 10–12% (w/v) SDS-polyacrylamide gels (Criter-
ion TGX, Bio-Rad, Munich, Germany), after which
proteins were transferred to PVDF membranes using the
Trans-Blot Turbo system (Bio-Rad). Blots were
incubated overnight at 4 °C with primary antibodies
(Table 1) diluted in TBS (Tris-buffered saline) contain-
ing 1% (w/v) Triton-X100, followed by incubation with
the appropriate peroxidase-conjugated secondary anti-
body (Table 1). Proteins were visualized using the Pierce®
ECL Western Blotting Substrate (ThermoFisher Scien-
tific, Waltham, MA, USA), and quantified using Chemi-
Doc™ Touch Imaging System (Bio-Rad).
RNA isolation and quantitative PCR
Total RNA from individual retinas was extracted using
TRIzol Reagent, and 2.5 μg of RNA was typically reverse
transcribed using the Superscript III Kit and random
primers (all from ThermoFisher Scientific). Quantitative
PCR (qPCR) was performed with the ABI Prism
7900HT Sequence Detection System using TaqMan Uni-
versal PCR Master Mix, no-AmpErase UNG, and Taq-
man assays (listed below) for detection (all from Thermo
Fisher). The relative change in gene expression was cal-
culated using the 2ΔCt method, normalizing to
expression levels of the Tbp (TATA-binding protein)
gene. The primer-probe sets used are listed in Table 2.
Statistical analysis
Statistical analyses were performed with GraphPad Prism
software 6.0 (GraphPad Software Inc., La Jolla, CA, USA).
Protein levels were compared using an unpaired t-test.
Gene expression levels were compared using either one-
way or 2-way ANOVA tests as indicated in the Figure
Table 1 Antibodies
Antibody against Host
species
Dilution Manufacturer Catalog
number
Rhodopsin Mouse IH,1:500 Abcam, Cambridge, UK AB3267
L/M-opsin Rabbit IH,1:200 Abcam AB5405
Mouse-Igs, Rabbit-Igs Alexa
488-546-647 labeled
Goat IH, 1:200–500 ThermoFisher Scientific, Waltham, MA A-11001
A-11008
A-11004
A-11011
A-21235
GSK-3Ββ Mouse IH,1:100 Cell Signaling Technology, Danvers,
Massachusetts, USA
9832S
pGSK-3ΒβS9 Mouse IH,1:400 Cell Signaling Technology 93,235
Recoverin Rabbit WB,1:5000 Millipore, Billerica, Massachusetts, USA AB5585
GSK-3Ββ Mouse WB,1:1000 Cell Signaling Technology 9832S
pGSK-3ΒβS9 Rabbit WB,1:1000 Cell Signaling Technology 93,235
Akt Rabbit WB,1:1000 Cell Signaling Technology 9272
pAktS473 Rabbit WB,1:1000 Cell Signaling Technology 9271 L
pAktS473 Rabbit IH,1:100 Cell Signaling Technology 4060
GFAP Rabbit IH, 1:500 Dako, Glostrup (Denmark) Z0334
IH immunohistochemistry, WB Western blot
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Legend. For ERG data, differences in wave amplitudes
over time between vehicle- and VP3.15-treated mice were
assessed using a 2-way ANOVA. Histological differences
between vehicle- and VP3.15-treated mice were assessed
by 2-way ANOVA. In all cases, p-values ≤0.05 were con-
sidered statistically significant.
Results
Inflammatory genes are upregulated in rd10 mice during
the early stages of retinal neurodegeneration
Pathological neuroinflammation is a hallmark of neuro-
degeneration in many retinal dystrophies [2–5]. We ana-
lyzed temporal alterations in pro-inflammatory gene
expression in the rd10 retina between P14 (before the
appearance of morphological signs of retinal degener-
ation) and P21 (at which stage the degenerative process
has become clearly established) to identify the optimal
period for therapeutic intervention. Quantitative PCR
analysis of WT and rd10 retinas revealed increased ex-
pression of the pro-inflammatory markers α2m, Il1β and
Tnfα in the degenerating retinas, beginning in the early
stages of degeneration (P18) and increasing dramatically
(by 25 to 50 fold) by P21 (Fig. 1). Reactive gliosis in re-
sponse to retinal damage, as measured by upregulated
Gfap expression, correlated with the increased expres-
sion of inflammatory markers. Likewise, the expression
of the microglia genes Cd68 and Cd11b also showed a
4–5 fold increase (Fig. 1).
GSK-3β expression in wild type and rd10 retinas
We next determined expression levels of GSK-3β, the
most abundant GSK-3 isoform in the CNS [6], during
the same degenerative period as above. We measured
the expression of total GSK-3β and of its inactive Ser9-
phosphorylated form (GSK-3βSer9) in rd10 mouse
retinas. No significant differences in GSK-3β RNA levels
were observed between rd10 and WT retinas (Fig. 2a).
Furthermore, despite the morphological differences
caused by the degenerative process, we observed similarly
broad distribution patterns for GSK-3β protein in both
P21 rd10 and WT retinas (Fig. 2b).
GSK-3β is an unusual kinase in that it is constitutively
activated but is inhibited upon stimulation of its regula-
tory signaling pathways (reviewed in [7]). Activation of
the PI3K/Akt pathway induces phosphorylation of GSK-
3β at Ser9, and subsequent downregulation of GSK-3β
activity [15]. During early retinal degeneration (P16 and
P18), no differences in Ser473-phosphorylated Akt
(pAktSer473) or Ser9-phosphorylated GSK-3β (pGSK-
3βSer9) levels were observed between WT and rd10
retinas (data not shown). Conversely, at P19 and P21, at
which point the degenerative process is well established,
as evidenced by decreased expression of the
photoreceptor protein recoverin, pAktSer473 and pGSK-
3βSer9 levels were significantly higher in rd10 versus WT
retinas (Fig. 3a and b). These observations in retinal
extracts were in agreement with the immunostaining
pattern observed at P21, which showed an increment in
pAktSer473 and pGSK-3βSer9 in the rd10 retina (Fig. 3c).
Table 2 Taqman assays
Gene Taqman assay
α2m Mm00558642_m1
Gfap Mm01253033_m1
Il1β Mm00434228_m1
Tbp Mm00446971_m1
Tnfα Mm00443260_g1
Rho Mm01184405_m1
Iba1 Mm00479862_g1
Cd68 Mm03047343_m1
Cd11b Mm00434455_m1
Fig. 1 Expression of inflammatory genes in the retina. RT-qPCR of WT
and rd10 retinas at the indicated ages. Levels of different transcripts
were normalized to those of Tbp RNA and relativized to P14 WT level
(= 1). Results represent the mean + SEM. n = 3–4, *p≤ 0.05, **p≤ 0. 01,
***p≤ 0.001, **** p≤ 0.0001 (2-way ANOVA)
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This inhibitory phosphorylation of GSK-3β, which coin-
cided with activation of the pro-survival Akt signaling
pathway, may represent an intrinsic neuroprotective re-
sponse to the genetic damage caused in the retina. To
test this hypothesis, we sought to potentiate this intrinsic
response by pharmacologically inhibiting GSK-3 activity.
In vivo VP3.15 treatment decreases inflammatory and
degenerative signs in the rd10 mouse retina
In light of our findings concerning proinflammatory
gene expression and GSK-3β modulation, we selected
the P15–P21 interval to assess the effects of short-term
treatment with VP3.15, a GSK-3 inhibitor. VP3.15 inhibi-
tory activity on GSK-3 was confirmed by determining its
effect on the β-catenin levels in the microglia cell line
N9 (Additional file 3: Figure S3). rd10 littermates re-
ceived daily intraperitoneal injections of either vehicle or
VP3.15 (10 mg/kg). One eye from each animal was ana-
lyzed for gene expression and the other for retinal
morphology. VP3.15 treatment significantly decreased
the expression of the proinflammatory genes Il1β and
α2m. A similar trend was observed for Tnfα expres-
sion (Fig. 4a), and secretion by rd10 retinal explants
(Additional file 7: Figure S7b), although these failed
to reach statistical significance. The microglia genes
b
a
Fig. 2 GSK-3β expression in the retina. a RT-qPCR of WT and rd10 retinas
at the indicated ages. Gsk-3β transcript levels were normalized to Tbp
RNA levels and relativized to P14 WT level (= 1). Results represent the
mean + SEM. n= 4. b Representative images of P21 retinal sections from
WT and rd10 mice, immunostained for GSK-3β (green). Nuclei are stained
with DAPI (blue). ONL, outer nuclear layer; INL, inner nuclear layer; GCL,
ganglion cell layer. Scale bar: 60 μm
b
c
a
Fig. 3 GSK-3β activation in the retina. a Representative Western blots
of protein extracts from WT and rd10 retinas (at P19 and P21). b
Densitometric analysis of several membranes as those shown in a.
Levels of phosphorylated Akt and GSK-3β were normalized to those of
total Akt and GSK-3β, respectively. Results represent the mean + SEM.
n = 4–5, *p≤ 0.05 (unpaired 2-tailed Student’s t test). c Representative
images of P21 retinal sections from WT and rd10 mice, immunostained
for pAktSer473 and pGSK-3βSer9 (green). Nuclei are stained with DAPI
(blue). ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion
cell layer. Scale bar: 60 μm
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Cd11b and Iba1 were also decreased upon VP3.15
treatment, while the activated microglia marker Cd68
showed a decline trend (Fig. 4b). In parallel, VP3.15
significantly reduced the expression of Gfap, an effect that
correlates with a reduced GFAP staining depicted by the
radial process of Müller glial cells and by the most inner
retinal layer formed by Müller end feet and astrocytes
(Fig. 4c and d). Conversely, a trend towards increased gene
expression of rod photoreceptor-specific rhodopsin was
observed in VP3.15-treated rd10 mice (Fig. 4e). This ob-
servation correlated with the maintenance of ONL thick-
ness and OS length, both of which were better preserved
in VP3.15-treated than in the vehicle-treated rd10 mice
(Fig. 4f). Moreover, while rhodopsin expression was spe-
cifically localized in the photoreceptor outer segment (OS)
in WT and VP3.15-treated rd10 retinas, vehicle-treated
rd10 retinas displayed shortening of the OS and mislocali-
zation of rhodopsin in the ONL (Fig. 4f).
b
c d
e f
a
Fig. 4 In vivo effect of short-term VP3.15 administration. rd10 mice received daily intraperitoneal injections of vehicle or VP3.15 from P15 to P21, and
were analyzed one day after the last injection (P22). a-c and e RT-qPCR of WT as well as untreated rd10 retinas, and vehicle- and VP3.15-treated rd10
retinas (all harvested at P22). Levels of all transcripts were normalized to those of Tbp RNA and relativized to WT levels (= 1). Results represent the
mean + SEM. n = 2–4, *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001, **** p≤ 0.0001 (one-way ANOVA). d and f Representative images of P22 retinal sections from
WT mice and from vehicle- and VP3.15-treated rd10 mice, immunostained for GFAP (d, red) and rhodopsin (f, cyan). Nuclei are stained with DAPI. In d
arrows point to the radial processes of Müller cells and the arrow head to the most inner retinal layer containing the Müller end feet and astrocytes.
Arrows in f point to mislocalized rhodopsin in the ONL. OS, outer segments; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion cell layer.
Scale bar: 60 μm
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In vivo treatment of rd10 mice with VP3.15 delays the
loss of visual function
Based on the promising results obtained following short-
term GSK-3 inhibition, we investigated whether a longer
treatment period preserved visual function in the rd10
mouse model. rd10 littermates received daily injections
of either vehicle or VP3.15 from P15 to P46 inclusive.
Visual function was assessed weekly by ERG between P25
and P46. Compared with vehicle-treated counterparts,
VP3.15-treated rd10 mice displayed better-defined ERG
waves of greater amplitude (Fig. 5 and Additional file 4:
Figure S4). The amplitude of ERG waves (a-mixed, b-
mixed, b-photopic, and oscillatory potential [OP]) was sig-
nificantly higher in VP3.15-treated than in vehicle-treated
mice, indicating a prolongation of both rod- and cone-
mediated vision function by VP3.15 (Fig. 5).
Histological evaluation of retinas at the end point of
the study (P47, after the last ERG) revealed a greater
relative ONL thickness in VP3.15- versus vehicle-
treated retinas despite the advanced degeneration stage
(Fig. 6a and b). The photoreceptor preservation effect
of VP3.15 was more evident at mid-degeneration stages
(P33; Additional file 5: Figure S5). Moreover, specific
immunostaining showed better preservation of photo-
receptor structure in VP3.15-treated retinas (Fig. 6a).
Rhodopsin immunostaining in rod outer segments
confirmed the partial preservation of rod outer seg-
ments in VP3.15-treated retinas. By contrast, rod
outer segments were barely present in vehicle-treated
retinas. Similarly, M-L opsin immunostaining revealed
longer cone outer segments in VP3.15- versus vehicle-
treated rd10 retinas (Fig. 6a and b).
Moreover, no toxic effect of VP3.15 administration
was observed in other neuronal populations of the
retina, particularly rod-bipolar and ganglion cells
(Additional file 6: Figure S6).
Taken together, these results demonstrate a neuropro-
tective effect of VP3.15 on neuroinflammation, retinal
structure, and visual function. Our findings thus support
the potential of VP3.15 as a novel therapy for retinal
dystrophies.
Discussion
This study describes GSK-3β expression and activation
of the Akt-GSK-3β pathway during the early stages of
retinal neurodegeneration in the rd10 mouse model of
RP. Our findings support the involvement of GSK-3 in
retinal decay and provide proof of concept of the neuro-
protective effect of GSK-3 inhibition on photoreceptor
cells [10]. In vivo administration of VP3.15, a small-
molecule GSK-3 inhibitor, reduced photoreceptor cell
loss and extended visual function. This neuroprotective
effect was accompanied by a decrease in the expression
of neuroinflammatory genes in the retina, indicating the
potential of VP3.15 as a candidate RP therapy.
GSK-3 is a constitutively activated multitask enzyme,
the activity of which is regulated by several inhibitory
signaling pathways [7]. Inhibitory phosphorylation of
GSK-3 at Ser9 is one of the main regulatory mecha-
nisms. Our analysis of GSK-3β RNA and protein levels
during the degenerative period in rd10 retinas revealed
no differences with respect to WT counterparts. How-
ever, at both P19 and P21, by when photoreceptor de-
generation is well established, inhibitory phosphorylation
of GSK-3β at Ser9, and phosphorylation of its Akt regu-
lator, were increased in rd10 retinas. This endogenous
activation of the prosurvival Akt-GSK-3β pathway in the
rd10 retina is in agreement with previous observations
in a photoreceptor cell line subjected to a variety of in-
sults, and in the dystrophic retina [16, 17]. We speculate
that the activation of endogenous prosurvival pathways
in the dystrophic retina constitutes an attempt to control
the degenerative process, a response that, however, re-
sults insufficient to counteract the permanent genetic
damage underlying the degeneration. In our experi-
ments, administration of the GSK-3 inhibitor VP3.15
may have exogenously potentiated the prosurvival
pathway, thus delaying photoreceptor cell death and pre-
serving visual function. Indeed, several agents with
neuroprotective effects in the retina exert common
stimulatory effects on the Akt-GSK-3β pathway [18–20].
GSK-3 is a downstream substrate of the insulin receptor
[15, 21] and is thus inhibited upon insulin receptor
Fig. 5 In vivo effect of long-term VP3.15 administration on visual
function. rd10 mice received daily intraperitoneal injections of vehicle
or VP3.15 from P15 to P45. ERG were performed at the indicated ages.
Graphs show averaged ERG wave amplitudes, plotted as a function of
animal age. Results represent the mean ± SEM. n = 10, **** p≤ 0.0001
(2-way ANOVA)
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stimulation. We have previously demonstrated that pro-
insulin, which binds with high affinity to the A isoform
of the insulin receptor in the retina and activates Akt
[22, 23], similarly prolongs rod survival and preserves
visual function [14, 22, 24].
Neuroinflammation is a key component of neurode-
generative processes affecting the brain and retina, and
thus constitutes a promising non-cell-autonomous target
for treatments of CNS diseases in general, and of the
retina in particular [2–5, 25]. GSK-3 plays a pivotal role
in the regulation of peripheral and central pro-
inflammatory cytokine production [26, 27], and its
inhibition reduces both systemic and brain inflammation
[26, 27]. The specific molecular events that occur in the
rd10 retina upon GSK-3 inhibition remain to be estab-
lished. This is a complicated task since GSK-3 is impli-
cated in the regulation of multiple cellular processes
including metabolism, cell structure, cell death, prolifer-
ation, and gene expression, with over 100 confirmed and
500 predicted substrates [7]. Exploratory studies employ-
ing rd10 retinal explants showed that VP3.15 attenuated
NF-kB activation (Additional file 7: Figure S7). NF-kB is
a key regulator of the inflammatory response by enabling
the transcription of the genes encoding many pro-
inflammatory cytokines. Indeed, our results suggest that
levels of pro-inflammatory cytokines (Il1β and Tnfα) are
reduced in VP3.15-treated rd10 retinas. This could ex-
plain, at least in part, the attenuation of photoreceptor
degeneration and loss, and the preservation of vision.
Moreover, the reduced inflammatory response observed
in VP3.15-treated retinas was accompanied by decreases
in the reactive gliosis marker GFAP as well as in α2M
expression, for which a role in retinal neurodegeneration
has been recently described [28–30].
In addition to its inhibitory effect on GSK-3, VP3.15 also
acts as an allosteric inhibitor of PDE7, an effect that con-
tributes to its neuroprotective activity in other CNS path-
ologies [13]. However, PDE7 inhibition, via increasing
cAMP levels and PKA activation, also converges on GSK-
3 inhibition [31]. PKA is able to phosphorylate GSK-3β at
Ser9 and, subsequently, to inactivate it [20, 31]. Besides,
previous findings by our group support that the prosurvi-
val effect of VP3.15 in photoreceptors may be primarily
due to GSK-3 inhibition, since the specific GSK-3 inhibi-
tor tideglusib exerted an even more potent neuroprotec-
tive effect in photoreceptors [10].
Most forms of RP involve primary death of rod photo-
receptors, in which the mutated gene exerts its function,
followed by secondary loss of cone photoreceptors. VP3.
15 treatment prolonged photoreceptor survival, as evi-
denced by the preservation of ONL thickness and rod
outer segment length. Furthermore, VP3.15 preserved
the integrity of the cone outer segment, the first site of
morphological alterations during cone degeneration. Hu-
man vision primarily relies on cones, which mediate day-
light, color, and high-acuity vision. Accordingly, a
mutation-independent treatment for RP that specifically
prolongs cone survival would be highly beneficial. VP3.
15 had a marked effect on cone cytoarchitecture and
visual function, as indicated by an increase in the
b
a
Fig. 6 In vivo effect of long-term VP3.15 administration on photoreceptor cell preservation. Retinal sections from the same animals described in Fig. 5
were immunostained to assess photoreceptor cell structure. a Representative images of P47 retinal sections from vehicle- and VP3.15-treated rd10 mice
immunostained for rhodopsin (cyan) and M/L opsin (green). Nuclei are stained with DAPI (blue). OS, outer segments; ONL, outer nuclear layer; INL,
inner nuclear layer; GCL, ganglion cell layer. Scale bar: 60 μm. b ONL and INL thickness and the length of rod and cone outer segments were measured
in equatorial sections corresponding to 6 regions of the retina, following a nasotemporal sequence (T1–T6; see Methods and Additional file 2: Figure
S2). Plots show the mean + SEM. n = 5 mice, 3 sections per retina, 3 measurements per region and section. ON, optic nerve. ***p≤ 0.001, **** p≤
0.0001 (2-way ANOVA)
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amplitude of the photopic b-wave compared with the
untreated rd10 animals. It remains unclear whether VP3.
15 exerts a direct effect on cone integrity, or whether
this effect is secondary to the prosurvival effect on rods
(present study and [10]). Regardless, VP3.15 resulted in
a marked attenuation of the loss of both daylight and
dim-light vision.
Conclusion
Our in vivo findings, together with the results of a re-
cently published in vitro study [10], support the thera-
peutic potential of GSK-3 modulation for the treatment
of retinal neurodegeneration, as described for other neu-
rodegenerative diseases [32], and underscore the potential
of GSK-3 inhibitors, in particular VP3.15, as pharmaco-
logical therapies for RP.
Additional files
Additional file 1: Figure S1. Chemical structure of VP3.15. (PPTX 49 kb)
Additional file 2: Figure S2. Scheme of the retinal sections. The 6
retinal zones defined for quantification as T1, T2, T3, T4, T5 and T6 are
indicated. ON, optic nerve. (PPTX 593 kb)
Additional file 3: Figure S3. Effect of VP3.15 on β-catenin levels. N9
microglia cell cultures were treated either with vehicle or with 10 μM
VP3.15 for 1 or 7 h. a Representative Western blots of protein extracts
from cultured N9 cells at the indicated times. b Densitometric analysis of
membranes as those shown in a. Levels of β-catenin were normalized to
those of GAPDH. Results represent the mean + SEM. n = 3, *p ≤ 0.05 (un-
paired 2-tailed Student’s t test). Methods are provided in Additional file 8.
(PPTX 11435 kb)
Additional file 4: Figure S4. VP3.15 treated mice show better light-
evoked responses than vehicle-treated ones. Standard ERG representative
trace recordings from one VP3.15-treated and one vehicle-treated over-
night dark-adapted animal. See for comparison the differences between
the two experimental groups in the trace amplitudes. Rod and cone
mixed response (a-mixed and b-mixed, 1.5 log cd·s/m2), and oscillatory
potential (OP, 1.5 log cd·s/m2) were recorded sequentially under scotopic
conditions. Cone (b-phot, 2 log cd·s/m2) responses were recorded after
5 min light-adaptation (30 cd/m2 background light) under photopic
conditions. All light responses were separated in the vertical axis to
better present the ERG waveform. Animal age is indicated to the left of
each trace recording. (PPTX 1167 kb)
Additional file 5: Figure S5. Mid-term effect of VP3.15 on photorecep-
tor preservation. rd10 mice received daily an intraperitoneal injection of
vehicle or VP3.15 from P15 to P32 and the retinas were analyzed one day
after the last injection (P33). Representative images of P33 retinal sections
from WT and vehicle- and VP3.15-treated rd10 mice stained with DAPI
(blue). ONL, outer nuclear layer; INL, inner nuclear layer. Scale bar: 60 μm.
b ONL and INL thickness were measured in equatorial sections corre-
sponding to 6 regions of the retina, following a nasotemporal sequence
(T1–T6; see Methods and Additional file 2: Figure S2). Plot shows the mean
+ SEM. n = 3 mice, 3 sections per retina, 3 measurements per region and
section. ON, optic nerve. ****p≤ 0.0001 (2-way ANOVA). (PPTX 360 kb)
Additional file 6: Figure S6. In vivo effect of VP3.15 treatment on rod-
bipolar and ganglion cells. rd10 mice received daily an intraperitoneal in-
jection of vehicle or VP3.15 from P15 to P32 and the retinas were ana-
lyzed one day after the last injection (P33). a Representative images of
P33 retinal sections from vehicle- and VP3.15-treated rd10 mice, immuno-
stained for PKCα or RBPMS to label rod-bipolar or ganglion cells respect-
ively (green). Nuclei are stained with DAPI (blue). b The number of PKCα-
and RBPMS-positive cells were scored in equatorial sections correspond-
ing to 6 regions of the retina, following a nasotemporal sequence (T1–T6;
see Methods and Additional file 2: Figure S2). The plots show the mean
+ SEM. n = 3 mice, 3 sections per retina, 3 measurements per region and
section. ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion
cell layer. Scale bar: 38 μm. Methods are provided in Additional file 8.
(PPTX 924 kb)
Additional file 7: Figure S7. Effect of VP3.15 on NF-kB activation and
TNFα secretion. P22 rd10 retinas were cultured in the absence (vehicle)
or presence of 3.2 μM VP3.15 for 16 h. a Representative images showing
Western blots of protein extracts. b Densitometric analysis of membranes
as those shown in a. Levels of pNF-kBSer536 were normalized to those of
GAPDH. Results represent the mean + SEM. n = 5–6, *p ≤ 0.05 (unpaired 2-
tailed Student’s t test). c TNFα concentration was quantified in the culture
media by ELISA. Methods are provided in Additional file 8. (PPTX 6297 kb)
Additional file 8: Additional Methods. (DOCX 20 kb)
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